about
Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophagesThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionIdentification of the Rage-dependent gene regulatory network in a mouse model of skin inflammation.Myeloid cell function in MRP-14 (S100A9) null mice.c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesisA novel aspartic proteinase-like gene expressed in stratified epithelia and squamous cell carcinoma of the skin.Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.RAGE signaling sustains inflammation and promotes tumor development.Myeloid-derived suppressor cells in malignant melanoma.New therapeutic options for advanced non-resectable malignant melanoma.Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.Myeloid-derived suppressor cells and tumor escape from immune surveillance.CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis.Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients.Endothelial Notch1 Activity Facilitates Metastasis.D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.T cell responses in early-stage melanoma patients occur frequently and are not associated with humoral response.Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response.Predictive immune markers in advanced melanoma patients treated with ipilimumab.Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis.The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation.Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas.Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy.Homeostatic nuclear RAGE-ATM interaction is essential for efficient DNA repair.CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions.Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy.Extracorporal Shock Wave Therapy Enhances Receptor for Advanced Glycated End-Product-Dependent Flap Survival and Angiogenesis.Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.The GNAQ in the haystack: intramedullary meningeal melanocytoma of intermediate grade at T9-10 in a 58-year-old woman.Liquid Biopsy zur Überwachung von Melanompatienten.Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.Liquid biopsy to monitor melanoma patients.STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapyMultiple white cysts on face and trunk of a melanoma patient treated with vemurafenib
P50
Q27325462-2BF6C2A1-CB5D-4189-9D84-5BA5EBFFADE9Q28076760-0AC99ECC-3C3E-4193-ABDB-88551167856CQ33710953-B7F911CA-C007-462B-8D01-B82152420071Q34783815-75479987-9204-4827-A1A1-EDAF95FB1632Q35084895-176EF984-9961-4531-8F24-1C6A9FE76C4CQ35088185-2E0BE384-332F-4377-852E-7650C45985CAQ36153854-E09480E8-D893-4D2C-9FCE-2FD13002FAD2Q36502858-25AE9A3E-8458-4106-AAF5-C41F993F61F8Q38254999-D67B4A56-2318-40B8-9DD4-45A77A2BBA27Q38321800-21D3B7DA-A84F-4546-96A8-F2FC798FD1FFQ38944200-6364265D-CF25-43A5-BB62-B4EA18A5B1A3Q38992562-81A88867-D94C-466A-B8EB-A840FA6205BCQ39223523-D304E24E-D21C-4AEA-B704-34190A2E71EAQ39814040-6B1ACE00-8B69-4CAF-B577-8BDCE5653BB4Q40051084-FEAC7CE3-F253-4BB0-8D9B-A917F9D2AEDCQ40317866-313D6C9E-0F0C-440F-8A59-32E39C1C5BD3Q40489634-06700BEE-7D38-482D-BCC6-D36E7C98B114Q40752231-00A04BB2-C00F-4A06-9132-D59FB62414C4Q42038580-FBC45C79-9251-47D1-886C-F98FA39312F5Q42427603-5C62E2B5-28AF-4DC1-854D-E0DEF3F688A2Q44040266-3E904EE4-60E2-4071-B881-9A178630BDA4Q47270219-169628EA-7C24-46D6-A9C6-C892FE1BC1DDQ47611324-8E6EC3B7-7F4E-441B-AB56-2A44E52590B0Q47632566-B9FE6D30-8DB8-440E-AC3B-56498154B5AEQ47699459-87288C31-A412-42D0-8F3B-816EBDAF2782Q48615384-88B65825-26B9-43F0-95DE-4791545C814EQ49507285-0E7DA59B-37EB-461F-A446-4765107F75A2Q50139587-1A4C6223-C0A1-47B7-8F53-2FC790D0A550Q50906889-89151CA3-4542-4818-A5B0-839845BCDFBEQ50961950-7B26D0A6-DFB9-483E-8E6B-74381D09A8E0Q52592280-60D9CF60-8633-4F36-82AD-83BC943E40C8Q53490356-A28152CB-7F79-41B5-BDBB-EBB9BB081F30Q53704079-F5A42D76-E3A8-4600-9383-F1DF31035A39Q53706211-BCCE55FF-CE1D-43BC-8884-1791438FA082Q53706401-7435734C-3E8A-4E38-BC26-430C67C77AF3Q53802002-F46DAACD-A74B-47A9-9429-216727D1A963Q54227390-F0470BC0-93E4-4E5D-825B-BA578238BAE5Q54355723-809758B4-205F-4BA8-9423-0E403C269482Q85280703-0EEE1C0D-046F-4259-9922-DBB8F66381EEQ87633488-E0132B6F-D602-44C5-9177-F955D0F230F0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Christoffer Gebhardt
@ast
Christoffer Gebhardt
@en
Christoffer Gebhardt
@es
Christoffer Gebhardt
@nl
Christoffer Gebhardt
@sl
type
label
Christoffer Gebhardt
@ast
Christoffer Gebhardt
@en
Christoffer Gebhardt
@es
Christoffer Gebhardt
@nl
Christoffer Gebhardt
@sl
prefLabel
Christoffer Gebhardt
@ast
Christoffer Gebhardt
@en
Christoffer Gebhardt
@es
Christoffer Gebhardt
@nl
Christoffer Gebhardt
@sl
P108
P214
P106
P1153
8787205900
P21
P214
P2798
P31
P496
0000-0001-7090-9584
P7859
viaf-6042399